BiotechTube

Carbamazepine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Neuropathic Pain

Conditions

Neuropathic Pain

Trial Timeline

Dec 1, 2009 → —

NCT ID
NCT01089855

About Carbamazepine

Carbamazepine is a approved stage product being developed by Novartis for Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01089855. Target conditions include Neuropathic Pain.

What happened to similar drugs?

7 of 20 similar drugs in Neuropathic Pain were approved

Approved (7) Terminated (2) Active (13)
🔄YHD1119 + LyricaYuhanPhase 3
✅pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
🔄DS-5565 + placeboDaiichi SankyoPhase 3
🔄Mirogabalin + PlaceboDaiichi SankyoPhase 3
🔄DS-5565Daiichi SankyoPhase 3
🔄Placebo + MirogabalinDaiichi SankyoPhase 3
✅Duloxetine + Pregabalin + PlaceboShionogiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01089855ApprovedCompleted

Competing Products

20 competing products in Neuropathic Pain

See all competitors
ProductCompanyStageHype Score
CHF6467 activeComac MedicalPhase 1/2
22
LY3857210 + PlaceboEli LillyPhase 2
35
OK-101 0.05% + OK-101 0.1% + PlaceboOKYO PharmaPhase 2
17
YHD1119 + LyricaYuhanPhase 3
40
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
29
pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
43
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-1971a + placebo + pregabalinDaiichi SankyoPhase 2
27
DS-5565Daiichi SankyoPhase 3
40
Placebo + MirogabalinDaiichi SankyoPhase 3
40
QutenzaAstellas PharmaPre-clinical
26
Qutenza exposureAstellas PharmaPre-clinical
26
Duloxetine + Pregabalin + PlaceboShionogiApproved
43
LY3016859 + PlaceboEli LillyPhase 2
35
LY3556050 + PlaceboEli LillyPhase 2
27
LY3526318 + PlaceboEli LillyPhase 2
35
LY4065967 + PlaceboEli LillyPhase 2
42
LY3848575 + PlaceboEli LillyPhase 2
39
ABT-639 + pregabalin + PlaceboAbbViePhase 2
35